Intranasal pitavastatin attenuates seizures in different experimental models of epilepsy in mice

Epilepsy Behav. 2017 Oct:75:56-59. doi: 10.1016/j.yebeh.2017.07.004. Epub 2017 Aug 18.

Abstract

This study was carried out to evaluate the effect of intranasal pitavastatin (PVS) on pentylenetetrazole (PTZ)-induced seizures, increasing current electroshock (ICES) seizures, and status epilepticus in mice. Intranasal PVS, 0.5 and 1.0mg/kg, showed significant increase in latency to PTZ-induced seizures and ICES seizure threshold compared to control; however, the effects were dose-dependent and were more significant at higher dose. Further, intranasal PVS (1.0mg/kg) but not intravenous PVS (50.0mg/kg) showed effective protection against PTZ-induced status epilepticus. No impairment in cognitive functions was observed following intranasal PVS (1.0mg/kg), thus making it a prospective therapeutic approach for acute seizures and status epilepticus.

Keywords: Cognitive impairment; Epilepsy; Intranasal; Pitavastatin; Status epilepticus.

MeSH terms

  • Administration, Intranasal
  • Animals
  • Disease Models, Animal
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Male
  • Mice
  • Neuroprotective Agents / administration & dosage
  • Neuroprotective Agents / adverse effects
  • Neuroprotective Agents / pharmacology*
  • Prospective Studies
  • Quinolines / administration & dosage
  • Quinolines / adverse effects
  • Quinolines / pharmacology*
  • Seizures / drug therapy*
  • Status Epilepticus / prevention & control*

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Neuroprotective Agents
  • Quinolines
  • pitavastatin